LUND, Sweden, April 12, 2023 /PRNewswire/ — Today, the board of directors of Immunovia AB (publ) (“Immunovia” or the “Company”) announces the outcome of the rights issue of shares that was announced on 20 February 2023 (the “Rights Issue”). In total, 10,392,876 shares were subscribed for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.